JP2019528082A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528082A5
JP2019528082A5 JP2019517135A JP2019517135A JP2019528082A5 JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5 JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5
Authority
JP
Japan
Prior art keywords
domain
antibody
fusion protein
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019517135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/087620 external-priority patent/WO2017211321A1/zh
Publication of JP2019528082A publication Critical patent/JP2019528082A/ja
Publication of JP2019528082A5 publication Critical patent/JP2019528082A5/ja
Priority to JP2021088589A priority Critical patent/JP2021143186A/ja
Priority to JP2024087108A priority patent/JP2024112978A/ja
Pending legal-status Critical Current

Links

JP2019517135A 2016-06-08 2017-06-08 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 Pending JP2019528082A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021088589A JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2024087108A JP2024112978A (ja) 2016-06-08 2024-05-29 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610404956.7 2016-06-08
CN201610404956 2016-06-08
PCT/CN2017/087620 WO2017211321A1 (zh) 2016-06-08 2017-06-08 增强激动型抗体活性的抗体重链恒定区序列

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021088589A Division JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Publications (2)

Publication Number Publication Date
JP2019528082A JP2019528082A (ja) 2019-10-10
JP2019528082A5 true JP2019528082A5 (cg-RX-API-DMAC7.html) 2019-11-21

Family

ID=60578403

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019517135A Pending JP2019528082A (ja) 2016-06-08 2017-06-08 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2021088589A Pending JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2024087108A Pending JP2024112978A (ja) 2016-06-08 2024-05-29 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021088589A Pending JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2024087108A Pending JP2024112978A (ja) 2016-06-08 2024-05-29 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Country Status (5)

Country Link
US (1) US12145993B2 (cg-RX-API-DMAC7.html)
EP (1) EP3470424B1 (cg-RX-API-DMAC7.html)
JP (3) JP2019528082A (cg-RX-API-DMAC7.html)
CN (2) CN115304669A (cg-RX-API-DMAC7.html)
WO (1) WO2017211321A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028316A2 (en) 2015-06-30 2018-09-04 Sanford-Burnham Medical Research Institute btla fusion protein agonists and uses thereof
JP2019528082A (ja) * 2016-06-08 2019-10-10 シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
MX2020006372A (es) * 2017-12-19 2020-09-03 Univ Rockefeller Variantes de dominio de fc de igg humana con funcion efectora mejorada.
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
KR102813744B1 (ko) * 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
EP3887397A1 (en) * 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
AU2020256828A1 (en) * 2019-04-10 2021-11-18 Nankai University Anti-CD40 antibody and use thereof
CN110981958B (zh) * 2019-08-23 2020-10-20 四川大学华西医院 一种pd-l1抗体
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
IL293450A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins and uses thereof
CN110862455B (zh) * 2019-12-03 2021-12-21 源道隆（苏州）医学科技有限公司 可结合cd47的多肽及其应用
AU2020396825A1 (en) * 2019-12-03 2022-07-21 Shanghai Jiao Tong University School Of Medicine Antibody Fc region having enhanced FCγRIIB affinity
MX2022014974A (es) 2020-05-26 2023-01-11 Boehringer Ingelheim Int Anticuerpos anti-pd-1.
CN114591428B (zh) * 2020-12-04 2024-05-28 上海交通大学医学院 抗Dsg1抗体及其应用
KR102671409B1 (ko) * 2021-03-02 2024-05-31 진화섭 Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
AU2024329875A1 (en) * 2024-01-02 2025-07-17 Gempharmatech Co., Ltd Animal model generating humanized antibody and construction method thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
CA2565961A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
MX2007001559A (es) * 2004-08-03 2007-04-10 Transtech Pharma Inc Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso.
SG158158A1 (en) * 2004-12-22 2010-01-29 Centocor Inc Glp-1 agonists, compositions, methods and uses
EA200801174A1 (ru) * 2005-10-24 2009-02-27 Сентокор, Инк. Антитела-миметики glp-2, полипептиды, композиции, способы и применения
HUE028537T2 (en) * 2009-04-20 2016-12-28 Kyowa Hakko Kirin Co Ltd Built-in amino acid mutation IgG2 antibody
PL2654780T3 (pl) 2010-12-23 2017-07-31 Janssen Biotech, Inc Aktywne mutanty przeciwciała fc odporne na proteazy
KR20230005405A (ko) * 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
BR112014020821B1 (pt) 2012-02-24 2022-11-16 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica e método de produção de uma molécula de ligação a antígeno
US9890378B2 (en) * 2012-05-11 2018-02-13 Merck Sharp & Dohme Corp. Surface anchored light chain bait antibody display system
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
JP2016515544A (ja) * 2013-03-18 2016-05-30 バイオセルオーエックス プロダクツ ビー．ブイ． ヒト化抗ｃｄ１３４（ｏｘ４０）抗体およびその使用
ES2839087T3 (es) 2013-11-12 2021-07-05 Ogd2 Pharma Anticuerpo derivado de IGG1 humana con actividad pro-apoptótica
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
BR112016023948A2 (pt) * 2014-04-16 2018-01-30 Ucb Biopharma Sprl proteínas fc multiméricas
CA2949998A1 (en) * 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
MX2016016080A (es) * 2014-06-05 2017-05-09 Univ Arkansas Vacunas guiadas por anticuerpos y metodos de uso para generar respuestas imunitarias maduras rapidas.
ES2807182T3 (es) * 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
WO2016081746A2 (en) * 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
BR112018010172A2 (pt) * 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
JP2019528082A (ja) * 2016-06-08 2019-10-10 シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
AU2020396825A1 (en) * 2019-12-03 2022-07-21 Shanghai Jiao Tong University School Of Medicine Antibody Fc region having enhanced FCγRIIB affinity
JP2023524092A (ja) * 2020-05-01 2023-06-08 ボルト バイオセラピューティクス、インコーポレーテッド 抗デクチン－２抗体
CN114106174A (zh) * 2020-08-27 2022-03-01 苏州景涞医疗科技有限公司 低毒性抗ox40抗体、其药物组合物及应用

Similar Documents

Publication Publication Date Title
JP2019528082A5 (cg-RX-API-DMAC7.html)
US12384850B2 (en) Guidance and navigation control proteins and method of making and using thereof
CN107474136B (zh) 增强激动型抗体活性的抗体重链恒定区序列
JP2020530289A5 (cg-RX-API-DMAC7.html)
JP2020521452A (ja) 標的化免疫寛容
IL271325B2 (en) Guidance and navigation control proteins and method of making and using thereof
CA3174097A1 (en) T-cell modulatory polypeptides with conjugation sites and methods of use thereof
JP2017524367A5 (cg-RX-API-DMAC7.html)
JP2018512430A5 (cg-RX-API-DMAC7.html)
JP2018503399A5 (cg-RX-API-DMAC7.html)
CN107847587A (zh) Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗
JP2023541771A (ja) リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質
JP2017533207A5 (cg-RX-API-DMAC7.html)
CA3058262A1 (en) Chimeric polypeptides and methods of altering the membrane localization of the same
JPWO2020069133A5 (cg-RX-API-DMAC7.html)
CN114853903A (zh) Btla融合蛋白激动剂及其用途
CN115515981A (zh) 抗肿瘤相关抗原抗体及其用途
JP2023515196A (ja) 脂肪酸分子とコンジュゲートされた抗体及びその使用
WO2023147331A1 (en) Bispecific molecule with tunable affinity to a targetted antigen
WO2023177974A2 (en) Anti-mesothelin antibodies and uses thereof
EP4475880A2 (en) Anti-il13ra2 antibodies and uses thereof
KR20250102074A (ko) 항-5t4 항체 및 이의 용도
CN120187757A (zh) 抗EGFRvIII抗体及其用途
WO2024182475A2 (en) Anti-ror2 antibodies and uses thereof
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof